Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Respiratory syncytial virus F protein |
Clinical data | |
Trade names | Enflonsia |
Other names | MK-1654, clesrovimab-cfor |
AHFS/Drugs.com | Enflonsia |
License data |
|
Routes of administration | Intramuscular |
Drug class | Antiviral |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6526H10118N1732O2039S40 |
Molar mass | 146747.22 g·mol−1 |
Clesrovimab, sold under the brand name Enflonsia, is a fully human immunoglobulin G1 kappa monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection. [1] It is a respiratory syncytial virus (RSV) F protein-directed fusion inhibitor. [1] It was developed by Merck, [2] and was approved for medical use in the United States in June 2025. [3]
Clesrovimab is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season. [1]
Clesrovimab was approved for medical use in the United States in June 2025. [2] [4]
Clesrovimab is the international nonproprietary name. [5]
Clesrovimab is sold under the brand name Enflonsia. [1]